Renal Cell Carcinoma

Over the past year, the COVID-19 pandemic has continued to affect the dissemination of critical clinical study findings.

Combination therapy with cabozantinib and atezolizumab is associated with tolerability and antitumor activity across diverse renal-cell carcinoma histologies.

The hypoxia-inducible factor-2α inhibitor belzutifan had antitumor activity in treatment-naïve and pretreated disease.

In a phase 2 trial, atezolizumab plus bevacizumab showed promise after disease progression on monotherapy with atezolizumab or sunitinib.

In a phase 1b/2 study, lenvatinib plus pembrolizumab combination showed promise as first-line therapy and beyond.

Compared with sorafenib, tivozanib was associated with longer progression-free survival, higher rates of response, and better tolerability in the third-line setting and beyond.

In a phase 3 trial, nivolumab combined with cabozantinib improved progression-free survival and overall survival versus sunitinib as first-line therapy.

In a phase 3 trial, lenvatinib combined with pembrolizumab improved progression-free survival versus lenvatinib plus pembrolizumab or sunitinib and improved overall survival compared with sunitinib.

In a phase 3 study, adjuvant pembrolizumab after nephrectomy improved disease-free survival versus placebo in patients with high-risk disease.

Each year in the United States there are approximately 76,000 new cases of kidney cancer and almost 14,000 kidney cancer–related deaths.